Takeda sheds off-patent drugs to focus on innovation
Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion ($35.7 billion).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
10 December 2020 Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
10 December 2020 Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
10 December 2020 Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.